Preface ix
Contributors xi
I Introduction to the Current Scientific, Clinical, and Social Environment of Drug Discovery and Development
1 Current Social, Clinical, and Scientific Environment of Pharmaceutical R&D 3
Laszlo Urban, Jean-Pierre Valentin, Kenneth I Kaitin, and Jianling Wang
2 Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug-related ADRs 23
Teresa Kaserer, Veronika Temml, and Daniela Schuster
II Intelligent Integration and Extrapolation of Admet Data
3 ADMET Diagnosis Models 49
Bernard Faller, Suzanne Skolnik, and Jianling Wang
4 PATH (Probe ADME and Test Hypotheses): A Useful Approach Enabling Hypothesis-driven ADME Optimization 63
Leslie Bell, Suzanne Skolnik, and Dallas Bednarczyk
5 PK-MATRIXâ"A Permeability: Intrinsic Clearance System for Prediction, Classification, and Profiling of Pharmacokinetics and Drugâ"drug Interactions 89
Urban Fagerholm
6 Maximizing the Power of a Local Model for ADMET-property Prediction 103
Sebastien Ronseaux, Jeremy Beck, and Clayton Springer
7 Chemoinformatic and Chemogenomic Approach to ADMET 125
Virginie Y. Martiny, Ilza Pajeva, Michael Wiese, Andrew M. Davis, and Maria A. Miteva
8 Multiparameter Optimization of ADMET for Drug Design 145
Matthew D. Segall and Edmund J. Champness
9 PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models 167
Hannah M. Jones and Neil Parrott
10 Emerging Full Mechanistic Physiologically Based Modeling 189
Kiyohiko Sugano
11 Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery: A Translational Tool to Optimize Discovery Compounds Toward the Ideal Target-specific Profile 211
Patricia Schroeder
III Assessment and Mitigation of Critical Clinically Relevant Admet Risks in Drug Discovery and Development
12 In Vitroâ"In Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds 235
Christian Wagner and Jennifer B. Dressman
13 Evaluation of the Collective Impact of Passive Permeability and Active Transport on In Vivo Blood-brain Barrier and Gastrointestinal Drug Absorption 263
Donna A. Volpe, Hong Shen, and Praveen V. Balimane
14 Integrated Assessment of Drug Clearance and Cross-Species Scalability 291
Kevin Beaumont, James R. Gosset, and Chris E. Keefer
15 Practical Anticipation of Human Efficacious Doses and Pharmacokinetics using Preclinical In Vitro and In Vivo Data 319
Tycho Heimbach, Rakesh Gollen, and Handan He
16 Management and Mitigation of Human Drugâ"drug Interaction Risks in the Drug Discovery and Development Phases 353
Heidi J. Einolf and Imad Hanna
17 Integrated Assessment and Clinical Translation of In Vitro Off-target Safety Pharmacology Risks 397
Patrick Y. Muller and Christian F. Trendelenburg
18 Integrated Risk Assessment of Cardiovascular Safety in Drug Discovery 407
G¼l Erdemli and Ruth L. Martin
19 Drug-induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools 433
Donna M. Dambach
20 Carcinogenicity and Teratogenicity Assessment 467
Hans-J¶rg Martus, David Beckman, and Lutz Mueller
21 Nephrotoxicity: Development of Biomarkers for Preclinical and Clinical Application 491
Frank Dieterle and Estelle Marrer
IV Success Stories and Lessons Learned
22 Early Intervention with Formulation Strategies for Multidimensional Problems to Optimize for Success 507
Stephanie Dodd, Christina Capacci-Daniel, Christopher Towler, Riccardo Panicucci, and Keith Hoffmaster
23 Cytochrome P450-mediated Drug Interaction and Cardiovascular Safety: The Seldane to Allegra Transformation 523
F. Peter Guengerich
24 Clinical Toxicity Profile of VEGF Inhibitors 535
Mark P. S. Sie and Ferry A. L. M. Eskens
25 Cardiomyopathy: Drug Induced and Predisposed 555
Shirley A. Aguirre and Eileen R. Blasi
26 Safety Management by Pharmacokinetic Considerations: Ranibizumab (Lucentis) and Bevacizumab (Avastin) 569
Nicole H. Siegel and Manju L. Subramanian
Index 583
